MA48602A - Composés hétéroaryle substitués par un amide alkyle d'oxyde de phosphine en tant que modulateurs des réponses il-12, il-23 et/ou ifn alpha - Google Patents
Composés hétéroaryle substitués par un amide alkyle d'oxyde de phosphine en tant que modulateurs des réponses il-12, il-23 et/ou ifn alphaInfo
- Publication number
- MA48602A MA48602A MA048602A MA48602A MA48602A MA 48602 A MA48602 A MA 48602A MA 048602 A MA048602 A MA 048602A MA 48602 A MA48602 A MA 48602A MA 48602 A MA48602 A MA 48602A
- Authority
- MA
- Morocco
- Prior art keywords
- modulators
- phosphine oxide
- compounds substituted
- ifn alpha
- heteroaryl compounds
- Prior art date
Links
- -1 PHOSPHINE OXIDE AMIDE Chemical class 0.000 title 1
- 150000001875 compounds Chemical group 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/650905—Six-membered rings having the nitrogen atoms in the positions 1 and 2
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662433470P | 2016-12-13 | 2016-12-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA48602A true MA48602A (fr) | 2020-03-18 |
Family
ID=60888685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA048602A MA48602A (fr) | 2016-12-13 | 2017-12-12 | Composés hétéroaryle substitués par un amide alkyle d'oxyde de phosphine en tant que modulateurs des réponses il-12, il-23 et/ou ifn alpha |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10294256B2 (OSRAM) |
| EP (1) | EP3555111B1 (OSRAM) |
| JP (1) | JP7046092B2 (OSRAM) |
| KR (1) | KR102602558B1 (OSRAM) |
| CN (1) | CN110267964B (OSRAM) |
| AR (1) | AR110351A1 (OSRAM) |
| ES (1) | ES2907008T3 (OSRAM) |
| MA (1) | MA48602A (OSRAM) |
| TW (1) | TW201827423A (OSRAM) |
| WO (1) | WO2018111787A1 (OSRAM) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202004592TA (en) | 2017-11-21 | 2020-06-29 | Bristol Myers Squibb Co | Sulfone pyridine alkyl amide-substituted heteroaryl compounds |
| AR117398A1 (es) | 2018-03-12 | 2021-08-04 | Abbvie Inc | Inhibidores de la señalización mediada por tirosina cinasa 2 |
| JP7485609B2 (ja) * | 2018-03-22 | 2024-05-16 | ブリストル－マイヤーズ スクイブ カンパニー | ＩＬ－１２、ＩＬ－２３および／またはＩＦＮα応答のモジュレーターとして有用なピリジン含有ヘテロ環式化合物 |
| US20230049130A1 (en) * | 2020-01-19 | 2023-02-16 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Deucravacitinib crystal form, preparation method therefor and use thereof |
| US12492184B2 (en) | 2020-12-22 | 2025-12-09 | InventisBio Co., Ltd. | Heteroaryl compounds, preparation methods and uses thereof |
| US20240246944A1 (en) | 2021-03-16 | 2024-07-25 | Anrui Biomedical Technology (Guangzhou) Co., Ltd. | Amino heteroaryl compounds and compositions |
| CN115724830A (zh) * | 2021-08-31 | 2023-03-03 | 浙江文达医药科技有限公司 | 作为tyk2/jak1假激酶结构域(jh2)抑制剂的化合物及合成和使用方法 |
| US20250051338A1 (en) | 2021-10-25 | 2025-02-13 | Kymera Therapeutics, Inc. | Tyk2 degraders and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007501775A (ja) | 2003-08-07 | 2007-02-01 | ノバルティス アクチエンゲゼルシャフト | 免疫抑制剤としてのヒストンデアセチラーゼ阻害剤 |
| PL2300013T5 (pl) * | 2008-05-21 | 2025-04-28 | Takeda Pharmaceutical Company Limited | Pochodne fosforu jako inhibitor kinazy |
| TW201100441A (en) | 2009-06-01 | 2011-01-01 | Osi Pharm Inc | Amino pyrimidine anticancer compounds |
| EP2794569B1 (en) * | 2011-12-21 | 2017-05-10 | Biota Europe Ltd | Heterocyclic urea compounds |
| JP6469567B2 (ja) * | 2012-05-05 | 2019-02-13 | アリアド・ファーマシューティカルズ・インコーポレイテッド | Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物 |
| TWI620737B (zh) | 2012-11-08 | 2018-04-11 | 必治妥美雅史谷比公司 | 作爲ＩＬ－１２、ＩＬ－２３及／或ＩＦＮα反應調節劑之經烷基－醯胺取代之吡啶化合物 |
| SG10201706897TA (en) * | 2012-11-08 | 2017-09-28 | Bristol Myers Squibb Co | Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn alph responses |
| WO2014181287A1 (en) * | 2013-05-09 | 2014-11-13 | Piramal Enterprises Limited | Heterocyclyl compounds and uses thereof |
| TWI582077B (zh) * | 2013-11-07 | 2017-05-11 | 必治妥美雅史谷比公司 | 作爲ＩＬ－１２、ＩＬ－２３及／或ＩＦＮα反應調節劑之經烷基－醯胺取代之吡啶化合物 |
| EP2947460A1 (en) | 2014-05-22 | 2015-11-25 | Medizinische Universität Wien | Personalized therapy of inflammation-associated cancer using methods of assessing the susceptibility of a subject to the treatment with EGFR inhibitors/antagonists |
-
2017
- 2017-12-12 KR KR1020197019993A patent/KR102602558B1/ko active Active
- 2017-12-12 CN CN201780086194.3A patent/CN110267964B/zh active Active
- 2017-12-12 WO PCT/US2017/065665 patent/WO2018111787A1/en not_active Ceased
- 2017-12-12 AR ARP170103473A patent/AR110351A1/es unknown
- 2017-12-12 EP EP17822919.1A patent/EP3555111B1/en active Active
- 2017-12-12 US US15/838,434 patent/US10294256B2/en active Active
- 2017-12-12 TW TW106143529A patent/TW201827423A/zh unknown
- 2017-12-12 ES ES17822919T patent/ES2907008T3/es active Active
- 2017-12-12 MA MA048602A patent/MA48602A/fr unknown
- 2017-12-12 JP JP2019551913A patent/JP7046092B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020502268A (ja) | 2020-01-23 |
| JP7046092B2 (ja) | 2022-04-01 |
| KR102602558B1 (ko) | 2023-11-14 |
| EP3555111A1 (en) | 2019-10-23 |
| EP3555111B1 (en) | 2022-01-26 |
| ES2907008T3 (es) | 2022-04-21 |
| WO2018111787A1 (en) | 2018-06-21 |
| TW201827423A (zh) | 2018-08-01 |
| KR20190091536A (ko) | 2019-08-06 |
| US10294256B2 (en) | 2019-05-21 |
| CN110267964B (zh) | 2022-05-03 |
| US20180162889A1 (en) | 2018-06-14 |
| CN110267964A (zh) | 2019-09-20 |
| AR110351A1 (es) | 2019-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA48602A (fr) | Composés hétéroaryle substitués par un amide alkyle d'oxyde de phosphine en tant que modulateurs des réponses il-12, il-23 et/ou ifn alpha | |
| CL2022000448A1 (es) | Autoinyector (divisional solicitud no. 201903061) | |
| MA46453A (fr) | Composés imidazopyridazine utiles en tant que modulateurs de réponses il-12, il-23 et/ou ifn alpha | |
| MA46620A (fr) | Composés hétérobicycliques utiles en tant que modulateurs de réponses à il-12, il-23 et/ou ifn alpha | |
| BR112018010805A2 (pt) | mutantes de proteína f de rsv | |
| MA43709A (fr) | Composition pharmaceutique comprenant de l'empagliflozine et ses utilisations | |
| BR112018007395A2 (pt) | 2,4-di-hidróxi-nicotinamidas como agonistas de apj | |
| MA46098A (fr) | Méthodes de prévention ou de traitement de l'allergie par administration d'un antagoniste d'il-4 r | |
| BR112018074468A2 (pt) | anticorpos anti-cd40 e suas utilizações | |
| EP3488361A4 (en) | RECORD VOTE SYSTEM | |
| MA52123A (fr) | Dérivé de 6-pyrimidine-isoindole utilisé en tant qu'inhibiteur de erk1/2 | |
| MX2017003359A (es) | Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos. | |
| EP3452407A4 (en) | METHOD AND USES FOR REMOVED TRIGGERED PROTEASE ACTIVITY MEASUREMENTS | |
| EP3602528A4 (en) | EXERCISE DEVICE WITH PISTON SIMULATION FOR PRE-FILLED SYRINGE | |
| EP3790461C0 (en) | SENSING CANNULA SYSTEMS | |
| DK3240538T3 (da) | Anvendelse af masitinib til behandling af en underpopulation af patienter med amyotrofisk lateralsklerose | |
| BR112016016274A2 (pt) | Ponte da barreira hematoencefálica | |
| EP3875542A4 (en) | SILICONE EMULSION COMPOSITION | |
| BR112018005208A2 (pt) | Compostos heterocíclicos que contêm benzilamina e composições úteis contra infecção micobacteriana | |
| MY192425A (en) | Polymorphs | |
| CL2016001763A1 (es) | Antagonistas selectivos de nr2b | |
| MA45226A (fr) | Compositions et méthodes de traitement ou de prévention d'affections liées à l'oxalate | |
| MX394123B (es) | Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos | |
| EP3305292A4 (en) | PHARMACEUTICAL COMPOSITION OF A MEK INHIBITOR AND METHOD OF MANUFACTURING THEREOF | |
| ECSP17074919A (es) | Piroglutamato de vortioxetina |